ADVENTRX Pharmaceuticals to meet FDA to review its NDA for ANX-530 ADVENTRX Pharmaceuticals.

ADVENTRX Pharmaceuticals to meet FDA to review its NDA for ANX-530 ADVENTRX Pharmaceuticals, Inc. today announced that it’ll meet up with the U.S eddrugs2018.com . Food and Drug Administration in Washington D.C. During the last week of April 2010 to review the business’s New Drug Application for ANX-530 and the FDA’s refusal-to-document letter. ADVENTRX got requested a face-to-face ending up in the FDA to understand its requirements and define the path to an effective filing of an ANX-530 NDA at the earliest possible time. Culley, Chief Executive Officer of ADVENTRX. ADVENTRX submitted an NDA for ANX-530 to the FDA in December 2009.

ADVENTRX prices underwritten general public offering of common stock ADVENTRX Pharmaceuticals, Inc. today announced the prices of an underwritten general public offering of 21,250,000 shares of its common share and warrants exercisable for 10,625,000 additional shares at $0.80 per fixed combination of shares and warrants for gross proceeds of approximately $17 million.5 of a talk about.10 per share and a 5-year term. Rodman & Renshaw, LLC, a wholly possessed subsidiary of Rodman & Renshaw Capital Group, Inc. , is definitely acting as sole book-running manager for the offering. Â.